Yung Shin Pharm. Ind
CompanyTaiwan
Yung Shin Pharm. Ind develops one asset, approved (tenofovir disoproxil fumarate in chronic hepatitis B). Mostly small molecule acting on OCA2 and pol; based in Taiwan.
- 1
- Asset
- Furthest stage
- Approved
- 4
- Trials
- 9
- Signals
Pipeline
1Prodrug of tenofovir that inhibits hepatitis B viral polymerase, blocking viral DNA synthesis.
Approved, Small molecule, OCA2, pol, chronic hepatitis B, hepatitis b virus
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials4
- Signals20
- Similar companies6